ESTRO 2024 - Abstract Book

S1751

Clinical - Lung

ESTRO 2024

Lymph Nodes Other Lymph Nodes

13 (29%) 11 (24%) 7 (16%) 6 (13%) 5 (11%) 15 (33%)

6 (43%) 5 (36%) 5 (36%) 2 (14%) 1 (7.1%) 2 (14%)

7 (23%) 6 (19%) 2 (6.5%) 4 (13%) 4 (13%) 13 (42%)

Bone Liver

Adrenal

Brain

Other

TKI

as

First

Line

38 (84%)

11 (79%)

27 (87%)

Treatment

First TKI Regimen Osimertinib

15 (33%) 8 (18%) 8 (18%) 9 (20%) 4 (8.9%) 1 (2.2%)

15 (48%) 8 (26%) 8 (26%)

Erlotinib Gefitinib Crizotinib Alectinib Ceritinib

9 (64%) 4 (29%) 1 (7.1%)

Local therapies Fifty-five TKI regimens were included in the analyses (per patient, median 1; range 1-3). The regimens were prolonged with 83 separate LTs (per patient, median 1; range 1-7).

One kidney, one vertebral bone, and one brain metastasis were surgically resected, while most LTs were RT (97%). Patients receiving only palliative fractionations, only stereotactic techniques or a combination during TKI were 26, nine and nine, respectively. The most frequent metastatic sites for RT were in the brain, lungs, and bones, see Figure 1. Palliative fractionations were mostly used for intrathoracic and bone metastases, while stereotactic techniques were primarily used for brain metastases.

Figure 1. Radiotherapy techniques used in progressive sites.

Time endpoints The median TLT was 11.1 months (IQR 5.9-24.3). The median PFS2 was 4.9 months (95 % CI 3.8-8.0), while the